Taiho Pharmaceutical Co Ltd (TPC), a full-fledged oncology pharmaceutical company headquartered in Tokyo, has established Taiho Ventures LLC, a strategic corporate venture capital arm of TPC, in California, USA.

Taiho Ventures will be investing globally in the start-up companies that discover and develop innovative therapeutic products and/or drug-enabling platform technologies that demonstrate a clear potential to benefit cancer patients. With the support of Taiho's established expertise in the field of oncology product discovery and development, Taiho Ventures will provide financial resources and company outreach to build strategic alliances to help translate novel research and high potential drug candidates into cornerstone products. Initially, Taiho Ventures will make investments from the pooled amount of $ 50million.

In June 2014, TPC committed to invest $ 30million in Remiges BioPharma Fund and through Remiges' well-connected US-Japan cross border investment team, Taiho has been tapping into the US/Europe biotech start-up community to catalyze the company's R&D.

Establishing Taiho Ventures demonstrates the company's continuous commitment to create long-term relationships with external partners globally with the goal to bring novel cancer therapies to patients and redefine the way the world treats cancer.